linicalTrials.gov ID NCT06229366
Sponsor POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Local PI Di Maria Jiang
Conditions
- Prostate Cancer
- Metastatic Castration-resistant Prostate Cancer
- Oligometastatic Prostate Carcinoma
- Hormone Sensitive Prostate Cancer
The primary aim of the phase Ia study is to evaluate the safety and tolerability of [Ac-225]-PSMA-62 to determine the maximum tolerated dose (MTD). The primary aim of the randomized phase Ib dose optimization is to determine the recommended phase II doses (RP2D) for patients with mCRPC and OmHSPC. The aim of the phase II study for patients with mCRPC is to evaluate the efficacy of [Ac-225]-PSMA-62.